PRELIMINARY
`AMENDMENT
`Under CFR 1.115
`
`Address to:
`Mail Stop Patent Application
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Sir:
`
`Electronically Filed
`REGN-008CIPCON
`Attorney Docket No.
`To Be Assigned
`Confirmation No.
`Y ANCOPOULOS, GEORGE D.
`First Named Inventor
`To Be Assigned
`Application Number
`17 December 2015
`Filing Date
`To Be Assigned
`Group Art Unit
`To Be Assigned
`Examiner Name
`Title:
`"Use of a VEGF Antagonist to Treat Angiogenic
`Eye Disorders"
`
`Prior to the examination of the above-referenced application on the merits, please enter the
`amendments below.
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 1
`
`Joining Petitioner: Apotex
`
`

`

`Atty Dkt. No.: REGN-008CIPCON
`USSN: To Be Assigned
`
`AMENDMENTS TO THE CLAIMS
`
`1.
`
`(Currently Amended) A method for treating an angiogenic eye disorder in a patient,
`
`said method comprising sequentially administering to the patient a single initial dose of a VEGF
`
`antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more
`
`tertiary doses of the VEGF antagonist;
`
`wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose;
`
`and
`
`wherein each tertiary dose is administered at least 8 weel1:s afteF the immediately 1ueeediag
`
`ft6se on an as-needed/pro re nata (PRN) basis, based on visual and/or anatomical outcomes as
`
`assessed by a physician or other qualified medical professional;
`
`wherein the VEGF antagonist is a receptor-based chimeric molecule comprising (1) a
`
`VEGFRl component comprising amino acids 27 to 129 of SEQ ID N0:2; (2) a VEGFR2
`
`component comprising amino acids 130-231 of SEQ ID N0:2; and (3) a multimerization
`
`component comprising amino acids 232-457 of SEQ ID N0:2.
`
`2.
`
`(Original) The method of claim 1, wherein only a single secondary dose is administered
`
`to the patient, and wherein the single secondary dose is administered 4 weeks after the initial dose of the
`
`VEGF antagonist.
`
`3.
`
`(Original) The method of claim 1, wherein only two secondary doses are administered to
`
`the patient, and wherein each secondary dose is administered 4 weeks after the immediately preceding
`
`dose.
`
`4.
`
`5.
`
`6.
`
`(Canceled)
`
`(Canceled)
`
`(Original) The method of claim 1, wherein the angiogenic eye disorder is selected from
`
`the group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema,
`
`central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
`
`7.
`
`(Original) The method of claim 6, wherein the angiogenic eye disorder is age related
`
`macular degeneration.
`
`2
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 2
`
`Joining Petitioner: Apotex
`
`

`

`Atty Dkt. No.: REGN-008CIPCON
`USSN: To Be Assigned
`
`8.
`
`(Currently Amended) The method of claim 1, wherein all doses of the VEGF
`
`antagonist is RH RHti VECF RHtih0d)' 0F fFRgmeHt theFe0f, RH RHti VECF Feeept0F RHtih0dy 0F
`
`fFagmeHt theFe0f, 0F a VECF Feeept0F eased ehimeFie m0leeale are administered to the patient by
`
`topical administration or by intraocular administration.
`
`9. - 12. (Canceled)
`
`13
`
`(Currently Amended) The method of claim£ ti, wherein all doses of the VEGF
`
`antagonist are administered to the patient by intraocular administration.
`
`14.
`
`(Original) The method of claim 13, wherein the intraocular administration is intravitreal
`
`administration.
`
`15. - 17.
`
`(Canceled)
`
`18.
`
`(Currently Amended) The method of claim 1317, wherein all doses of the VEGF
`
`antagonist comprise from about 0.5 mg to about 2 mg of the VEGF antagonist.
`
`19.
`
`(Original) The method of claim 18, wherein all doses of the VEGF antagonist comprise
`
`0.5 mg of the VEGF antagonist.
`
`20.
`
`(Original) The method of claim 18, wherein all doses of the VEGF antagonist comprise 2
`
`mg of the VEGF antagonist.
`
`21.
`
`(New) The method of claim 1, wherein the VEGF antagonist is VEGFR1R2-Fcl'.1Cl(a)
`
`encoded by the nucleic acid sequence of SEQ ID NO: 1.
`
`3
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 3
`
`Joining Petitioner: Apotex
`
`

`

`REMARKS UNDER 37 CFR § 1.115
`
`Atty Dkt. No.: REGN-008CIPCON
`USSN: To Be Assigned
`
`Formal Matters
`
`Claims 1-3, 6-8, 13, 14 and 18-21 are pending after entry of the amendments set forth herein.
`
`Claims 4, 5, 9-12 and 15-17 are canceled without prejudice.
`
`Claims 1 and 8 are amended.
`
`Claim 21 is added.
`
`For the convenience of the Examiner, support for the claim amendments is made in part with
`
`reference to the allowed claims of the parent application.
`
`The amendments to claim 1 with respect to defining the VEGF antagonists are identical to
`
`allowed claim 1 of the parent application and supported within originally pending now cancelled claim
`
`11.
`
`The amendments to claim 1 with respect to the tertiary dose administration are supported in the
`
`original application in paragraph [0062] Example 5, Table 2 and in paragraph [0065] Example 6.
`
`The amendments to claim 8 are supported in originally pending now cancelled claim 12.
`
`Formal amendments are made to claims 13 and 18 in view of the cancellation of claims 12 and
`
`17.
`
`Newly added claim 21 is supported in the original specification in original paragraph [0034].
`
`No new matter has been added.
`
`PARENT APPLICATION
`
`The parent application has been allowed. Further, as indicated above, correspondence and
`
`support for the current claims relative to those of the parent application can be reviewed and confirmed.
`
`In the event the Examiner has any questions with respect to claim support or other issues in connection
`
`with the application, the Examiner is respectfully requested to contact the undersigned attorney at the
`
`indicated telephone number to arrange for an interview to expedite this position of this application.
`
`STATEMENT UNDER 37 C.F.R. §§1.56 AND 1.2
`
`Applicants hereby advise the Examiner of the status of a co-pending application in compliance
`
`with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 (see also MPEP §2001.06(b)) as
`
`4
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 4
`
`Joining Petitioner: Apotex
`
`

`

`Atty Dkt. No.: REGN-008CIPCON
`USSN: To Be Assigned
`
`discussed in McKesson Info. Soln. Inc., v. Bridge Medical Inc., 487 F.3d 897; 82 USPQ2d 1865 (Fed.
`
`Cir. 2007).
`
`The Applicants wish to bring to the Examiner's attention that a Notice of Allowance was mailed
`
`on October 19, 2015 in co-pending U.S. Patent Application No. 13/940,370, filed July 12, 2013.
`
`This document is (These documents are) available on PAIR, and thus is (are) not provided with
`
`this communication. Please inform the undersigned if there is any difficulty in obtaining the
`
`document(s) from PAIR.
`
`CONCLUSION
`
`Applicant submits that all of the claims are in condition for allowance, which action is requested.
`
`If the Examiner finds that a telephone conference would expedite the prosecution of this application,
`
`please telephone the undersigned at the number provided.
`
`The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of
`
`$3,000.00 beyond that authorized on the credit card, but not more than $3,000.00 in additional fees due
`
`with any communication for the above referenced patent application, including but not limited to any
`
`necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No.
`
`50-0815, order number REGN-008CIPCON.
`
`Respectfully submitted,
`BOZICEVIC, FIELD & FRANCIS LLP
`
`Date:
`
`17 December 2015
`---------~~-
`
`By: -~/_K_ar_l_B_o_z_ic_e_v_ic~,_R_e_g_._N_o_._2~8~,8~0~7~/­
`Karl Bozicevic
`Registration No. 28,807
`
`Bozicevic, Field & Francis LLP
`1900 University Avenue, Suite 200
`East Palo Alto, California 94303
`Telephone: (650) 327-3400
`Facsimile: (650) 327-3231
`
`5
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 5
`
`Joining Petitioner: Apotex
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`Title of Invention:
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`First Named Inventor/Applicant Name:
`
`GEORGE D. YANCOPOULOS
`
`Filer:
`
`Attorney Docket Number:
`
`Filed as Large Entity
`
`Filing Fees for Utility under 35 USC 111 (a)
`
`Karl Bozicevic
`
`REGN-008CIPCON
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Basic Filing:
`
`Utility application filing
`
`Utility Search Fee
`
`Utility Examination Fee
`
`1011
`
`1111
`
`1311
`
`1
`
`1
`
`1
`
`280
`
`600
`
`720
`
`280
`
`600
`
`720
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-Interference:
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 6
`
`Joining Petitioner: Apotex
`
`

`

`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Post-Allowance-and-Post-Issuance:
`
`Extension-of-Time:
`
`Miscellaneous:
`
`Total in USO($)
`
`1600
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 7
`
`Joining Petitioner: Apotex
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`24386727
`
`14972560
`
`International Application Number:
`
`Confirmation Number:
`
`5391
`
`Title of Invention:
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`First Named Inventor/Applicant Name:
`
`GEORGE D. YANCOPOULOS
`
`Customer Number:
`
`96387
`
`Filer:
`
`Karl Bozicevic
`
`Filer Authorized By:
`
`Attorney Docket Number:
`
`REGN-008CIPCON
`
`Receipt Date:
`
`17-DEC-2015
`
`Filing Date:
`
`Time Stamp:
`
`13:37:22
`
`Application Type:
`
`Utility under 35 USC 111 (a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`RAM confirmation Number
`
`Deposit Account
`
`Authorized User
`
`yes
`
`Credit Card
`
`$1600
`
`14282
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 8
`
`Joining Petitioner: Apotex
`
`

`

`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Name
`
`File Size(Bytes}/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(if appl.)
`
`1
`
`Application Data Sheet
`
`REGN-008CIPCON_ADS_Form.
`pdf
`
`1823449
`
`88c66bddce20d97a2c73c1228bf330d1 fec3
`1271
`
`no
`
`9
`
`Warnings:
`
`Information:
`
`2
`
`REGN-008CIPCON_Specificatio
`n.pdf
`
`529155
`
`66488c5 3 63 7f4 b771 5 ffe 32f0 b65 96663f6e(
`2cd
`
`yes
`
`24
`
`Multipart Description/PDF files in .zip description
`
`Document Description
`
`Start
`
`End
`
`Specification
`
`Claims
`
`Abstract
`
`Warnings:
`
`Information:
`
`3
`
`Drawings-only black and white line
`drawings
`
`Warnings:
`
`21
`
`23
`
`24
`
`1
`
`22
`
`24
`
`105393
`
`725A 1 _Figure.pdf
`
`no
`
`1
`
`2d582f64Sd0c5d 17d717e589b029a39331 ~
`91bdb
`
`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the
`Image File Wrapper and may affect subsequent processing
`
`Information:
`
`4
`
`Oath or Declaration filed
`
`Warnings:
`
`REGN-008CIPCON_declaration.
`pdf
`
`173097
`
`6bda7272374e6af80c8c3d8cf30d012e465
`b588
`
`no
`
`2
`
`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the
`Image File Wrapper and may affect subsequent processing
`
`Information:
`
`5
`
`Power of Attorney
`
`REGN_genl_poa_AIA.pdf
`
`no
`
`1
`
`108269
`
`313a44c6Sd8b016a8be66db301 5605716a
`908ae0
`
`Warnings:
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 9
`
`Joining Petitioner: Apotex
`
`

`

`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the
`Image File Wrapper and may affect subsequent processing
`
`Information:
`
`6
`
`Power of Attorney
`
`REGN-008CIP _assignment.pdf
`
`no
`
`2
`
`124971
`
`b00a0da52fe6f20e31 aeb6382a263b3bd0d
`8b965
`
`Warnings:
`
`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the
`Image File Wrapper and may affect subsequent processing
`
`Information:
`
`7
`
`Assignee showing of ownership per 37
`CFR 3.73
`
`REGN-008CIPCON_373_c.pdf
`
`no
`
`2
`
`32065
`
`1aba633f5f06d9ded97c9cf6a51 e919Sd60c
`2f9c
`
`Warnings:
`
`Information:
`
`8
`
`Miscellaneous Incoming Letter
`
`REGN-0008CIPCON_seq_list_tr
`ans.pdf
`
`26906
`
`78830cd5ee2f2e94a4bfd39a8233e 1 041 ab
`1b185
`
`no
`
`1
`
`Warnings:
`
`Information:
`
`9
`
`Sequence Listing (Text File)
`
`725A 1 _Seqlist.txt
`
`no
`
`0
`
`6076
`
`Warnings:
`
`Information:
`
`10
`
`Warnings:
`
`Information:
`
`REGN-008CIPCON_2015-12-17_
`pre_amend.pdf
`
`53261
`
`cca5f4501aa84517fbad59c527d4efda21 Oe
`016e
`
`yes
`
`5
`
`Multipart Description/PDF files in .zip description
`
`Document Description
`
`Start
`
`End
`
`Preliminary Amendment
`
`Claims
`
`Applicant Arguments/Remarks Made in an Amendment
`
`1
`
`3
`
`5
`
`1
`
`2
`
`4
`
`35018
`
`11
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`no
`
`2
`
`2c0cc6c7ff87f498016Sbd578c0e51138Sc7
`d8aa
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes)
`
`3017660
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 10
`
`Joining Petitioner: Apotex
`
`

`

`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT /DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 181 O), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/R0/1 OS) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 11
`
`Joining Petitioner: Apotex
`
`

`

`PTO/AIAf14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2:
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`11
`Legal Name
`
`Prefix Given Name
`
`I El J3eorge
`
`Residence Information (Select One)
`• US Residency
`I State/Province I t'JY
`frorktown Heights
`City
`
`Middle Name
`
`p.
`
`I Remove
`
`I
`
`Family Name
`
`fl'ANCOPOULOS
`Non US Residency
`Active US Military Service
`I Country of Residenc~ I f.Js
`
`Suffix
`
`I El
`
`Mailing Address of Inventor:
`
`Address 1
`
`~o Regeneron Pharmaceuticals, Inc.
`
`I lfarrytown
`City
`Postal Code
`
`Address 2
`
`lr77 Old Saw Mill River Road
`
`I State/Province
`I 11 os91-6101
`I Countryi
`11us
`All Inventors Must Be Listed - Additional Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`I ~y
`
`I Add
`
`I
`
`Correspondence Information:
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`36387
`
`Email Address
`
`docket@bozpal.com
`
`Application Information:
`
`I Add Email I
`
`I
`
`I Remove Email I
`
`Title of the Invention
`
`Attorney Docket Number REGN-008CIPCON
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`I Small Entity Status Claimed D
`
`Application Type
`
`Non provisional
`
`Subject Matter
`
`Utility
`
`Total Number of Drawing Sheets (if any)
`
`1
`11
`
`I Suggested Figure for Publication (if any) 111
`
`T
`
`T
`
`EFSWeb2.2.12
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 12
`
`Joining Petitioner: Apotex
`
`

`

`PTO/AIAf14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Filing By Reference:
`Only complete this section when filing an application by reference under 35 U.S.C. 111 (c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`i-
`
`I
`
`Publication Information:
`D Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`Request Not to Publish. I hereby request that the attached application not be published under
`D 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`Please Select One:
`
`Customer Number
`
`• Customer Number
`~6387
`
`I
`
`US Patent Practitioner IO Limited Recognition (37 CFR 11.9)
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the "Application Number" field blank.
`I·
`
`I Remove I
`
`Prior Application Status
`
`!='ending
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`I
`
`j:ontinuation of
`
`I· 13940370
`
`~013-07-12
`
`EFS Web 2.2.12
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 13
`
`Joining Petitioner: Apotex
`
`

`

`PTO/AIAf14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Prior Application Status
`
`t=xpired
`
`.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`~3940370
`
`Continuation in part of
`
`Prior Application Status
`
`~xpired
`
`Application Number
`
`Continuity Type
`
`tcT /US2012/020855
`
`Claims benefit of provisional
`
`Prior Application Status
`
`~xpired
`
`Application Number
`
`Continuity Type
`
`tcT /US2012/020855
`
`Claims benefit of provisional
`
`Prior Application Status Expired
`
`. PCT /US2012/020855
`.
`
`Prior Application Number
`
`. 61432245
`.
`
`Prior Application Number
`
`. 61434836
`.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`tcT /US2012/020855
`
`J:laims benefit of provisional
`
`. 61561957
`
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~012-01-11
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~011-01-13
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~011-01-21
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~011-11-21
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`I Add
`
`I
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX)i the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the POX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1 ).
`
`Application Number
`
`Filing Date (YYYY-MM-DD)
`I
`I
`I
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`Countryi
`
`I Remove I
`Access Codei (if applicable)
`
`I Add
`
`I
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`EFS Web 2.2.12
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 14
`
`Joining Petitioner: Apotex
`
`

`

`PTO/AIAf14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number REGN-008CIPCON
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16,2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`EFS Web 2.2.12
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 15
`
`Joining Petitioner: Apotex
`
`

`

`PTO/AIAf14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see
`paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph Bin subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Prioritv Document Exchange IPDXl - Unless box A in subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authoritv to provide the European Patent Office (EPO), the Japan Patent Office
`(JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of
`China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office
`participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign
`application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed
`and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the
`instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)
`(1 ).
`
`B. Search Results from U.S. Application to EPO - Unless box Bin subsection 2 (opt-out of authorization) is checked,
`the undersigned hereby grants the USPTO authoritv to provide the EPO access to the bibliographic data and search
`results from the instant patent application when a European patent application claiming priority to the instant patent
`application is filed. See 37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a
`copy of search results from the instant application without delay in a European patent application that claims priority to
`the instant application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`D application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with
`any documents and information identified in subsection 1A above.
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`D application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant
`application.
`NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the
`application in accordance with 37 CFR 1.14.
`
`EFS Web 2.2.12
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 16
`
`Joining Petitioner: Apotex
`
`

`

`PTO/AIAf14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Tille 37 of CFR
`to have an assignment recorded by the Office.
`
`I Remove I
`Applicant
`11
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`I Clear
`
`I
`
`Assignee
`
`I
`• Person to whom the inventor is obligated to assign .
`
`I
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Legal Representative under 35 U.S.C. 117
`
`Joint Inventor
`
`I
`Person who shows sufficient proprietary interest
`
`Name of the Deceased or Legally Incapacitated Inventor: I
`
`Organization Name
`
`If the Applicant is an Organization check here.
`~
`I ~EGENERON PHARMACEUTICALS, INC.
`Mailing Address Information For Applicant:
`
`1~1
`
`Address 1
`
`Address 2
`
`City
`Count..Y I t-Js
`Phone Number
`
`Email Address
`
`'77 Old Saw Mill River Road
`
`Tarrytown
`
`State/Province
`
`NY
`
`Postal Code
`
`Fax Number
`
`10591-6707
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`I Add
`
`I
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title
`37 of CFR to have an assignment recorded by the Office.
`
`EFS Web 2.2.12
`
`Mylan Exhibit 1017
`Mylan v. Regeneron, IPR2021-00880
`Page 17
`
`Joining Petitioner: Apotex
`
`

`

`PTO/AIAf14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number REGN-008CIPCON
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Assignee
`
`l1
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`Organization Name
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`I ~EGENERON PHARMACEUTICALS, INC.
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`I Remove I
`~
`
`rr11 Old Saw Mill River Road
`
`I I
`lrarrytown
`
`Address 1
`
`Address 2
`
`City
`
`Coun